TD Cowen Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $5

Futu News21:32 · Ratings

VYNE Therapeutics | 10-Q: Quarterly report

SEC05:14 · Announcements

H.C. Wainwright Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $5.75

Futu NewsNov 7 23:31 · Ratings

LifeSci Capital Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $6

Futu NewsNov 7 23:31 · Ratings

VYNE Therapeutics: Promising Clinical Progress and Financial Stability Support Buy Rating

TipRanksNov 7 23:05 · Ratings

VYNE Therapeutics Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $121.000K Beat $110.000K Estimate

BenzingaNov 7 21:19